Physician profile
Nicole L Reid
NPI 1215089891
$28,720.56
in general payments reported to CMS, 2019-2025
27 companies · $42.39 in 2025
The $42.39 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $8,454 · 2021: $23.99 · 2022: $1,279 · 2023: $16K · 2024: $1,614 · 2025: $42.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,118 · Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,413.00 |
| Travel and Lodging | $3,117.72 |
| Food and Beverage | $1,259.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $17,988.96 | 2022-2024 | Puraply Antimicrobial, Puraply, Affinity |
| Intuitive Surgical, INC. | $9,540.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.25 | 2019-2023 | Jardiance |
| Amgen INC. | $130.25 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $122.41 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $118.88 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $78.05 | 2022-2024 | Farxiga, Andexxa |
| Medtronic, INC. | $70.45 | 2023 | Closurefast |
| Convatec INC. | $56.28 | 2023 | |
| Kci USA, INC. | $37.45 | 2019 | |
| Atricure, INC. | $36.96 | 2023 | |
| Tactile Systems Technology INC | $32.62 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Kowa Pharmaceuticals America, INC. | $32.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.07 | 2023 | Onpattro |
| Molnlycke Health Care US, LLC | $28.84 | 2025 | Exufiber Ag+, Mepilex Border, Tubigrip |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.17 | 2024 | Arcalyst |
| Solventum Corporation | $20.33 | 2024 | Kerramax Care, 3m Cavilon, Promogran Prisma |
| Kiniksa Pharmaceuticals, LTD. | $19.78 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $19.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2022 | |
| Acist Medical Systems, INC. | $19.15 | 2022 | |
| Corcept Therapeutics | $17.79 | 2023 | Korlym |
| Angiodynamics, INC. | $13.92 | 2022 | |
| Smith+Nephew, INC. | $13.55 | 2025 | Regranex, Collagenase Santyl |
| Teleflex LLC | $12.73 | 2023 | Guideliner |
| Karl Storz Endoscopy-America | $11.66 | 2022 | |
| Grifols USA, LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.